🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Nasdaq Gains 1%; Charles Schwab Earnings Top Views

Published 16/10/2023, 17:08
© Reuters.  Nasdaq Gains 1%; Charles Schwab Earnings Top Views
SCHW
-

Benzinga - by Lisa Levin, Benzinga Editor.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.

The Dow traded up 1.02% to 34,012.79 while the NASDAQ rose 1% to 13,541.79. The S&P 500 also rose, gaining, 1.03% to 4,372.52.

Check This Out: Top 3 Health Care Stocks That May Implode This Quarter

Leading and Lagging Sectors

Consumer discretionary shares climbed by 1.4% on Friday.

In trading on Friday, energy shares rose by just 0.5%.

Top Headline

The Charles Schwab Corporation (NYSE: SCHW) reported better-than-expected earnings for the third quarter.

The company posted quarterly net revenue decline of 16% year-over-year to $4.61 billion, missing the consensus of $4.63 billion. Adjusted EPS stood at $0.77, down 30% Y/Y, exceeding the consensus of $0.75.

Equities Trading UP

Consolidated Communications Holdings, Inc. (NASDAQ: CNSL) shares shot up 16% to $4.10 after the company announced an agreement to be acquired by Searchlight Capital Partners and British Columbia Investment Management.

Shares of PCTEL, Inc. (NASDAQ: PCTI) got a boost, shooting 47% to $6.87. On Friday, Amphenol Corp (NYSE: APH) inked a deal to acquire PCTEL for around $139.7 million.

E2open Parent Holdings, Inc. (NYSE: ETWO) shares were also up, gaining 26% to $3.09. Elliott Investment Management L.P. reported a 9% stake in E2open Parent Holdings as of Oct. 13.

Equities Trading DOWN

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares dropped 67% to $1.80. The company received feedback from the U.S. Food and Drug Administration (FDA) regarding their new drug application (NDA) for reproxalap, intended for treating dry eye disease.

Shares of Streamline Health Solutions, Inc. (NASDAQ: STRM) were down 67% to $0.2468 after the company announced it is undergoing a strategic restructuring to cut expenses.

Omeros Corporation (NASDAQ: OMER) was down, falling 39% to $1.38 after the company announced it will discontinue the ARTEMIS-IGAN trial, which did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo.

Also Check This Out: JPMorgan To Rally Over 29%? Here Are Top 10 Analyst Forecasts For Monday

Commodities

In commodity news, oil traded down 0.4% to $87.31 while gold traded down 0.4% at $1,934.00.

Silver traded down 0.4% to $22.805 on Friday while copper rose 0.3% to $3.5815.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 rose 0.38%, London’s FTSE 100 rose 0.59% while Spain’s IBEX 35 Index rose 0.68% The German DAX rose 0.42% French CAC 40 rose 0.45%, while Italy’s FTSE MIB Index gained 0.65%.

The Eurozone recorded a trade surplus of EUR 6.7 billion in August versus a year-ago gap of EUR 54.4 billion. The annual inflation rate in Italy eased to 5.3% in September from 5.4% a month ago. German wholesale prices fell for the sixth straight period by 4.1% year-over-year in September.

Asia Pacific Markets

Asian markets closed lower on Monday, with Japan’s Nikkei 225 falling 2.03%, China’s Shanghai Composite Index falling 0.46% and Hong Kong’s Hang Seng Index dropping 0.97%. India’s S&P BSE Sensex, meanwhile, slipped 0.2%.

India's wholesale prices fell by 0.26% year-over-year in September following a 0.52% decline in the previous month. Industrial production in Japan fell by 0.7% month-over-month in August.

Economics

The NY Empire State Manufacturing Index declined to -4.6 in October from 1.9 in the prior month, compared to market estimates for a reading of -7.

Now Read This: Rain Oncology And 3 Other Stocks Under $1 Insiders Are Buying

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.